Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Am J Kidney Dis. 2020 Aug 10;77(2):216–225. doi: 10.1053/j.ajkd.2020.04.014

Figure 1. Reduction in proteinuria from baseline to week-26 associated with slower rate of eGFR decline from week-26 onward. Results of adjusted linear mixed effects models (n=138 participants; n=752 observations).

Figure 1.

Model adjusted for APOL1 genotype, log-baseline UP:C, baseline eGFR, and treatment arm. Non-significant covariates removed during model selection include age, sex, race, systolic blood pressure index, and reduction in systolic blood pressure index (baseline - week 26). “Persistent proteinuria” refers to 0% reduction in UP:C. Multiple imputation by fully conditional specification was used to handle missing data. Observation “time” for eGFR outcome measurements=week 26 to last follow-up (maximum of month 54 from baseline).

Abbreviations: 95% CI, 95% confidence interval; APOL1, Apolipoprotein L1; eGFR, estimated glomerular filtration rate; UP:C, urine protein: creatinine ratio.